Inventor
KYLE DONALD J
US66 patents
⚠️ This page may combine multiple inventors who share the name “KYLE DONALD J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PURDUE PHARMA LP
19 patentsUS7683063B2Mar 23, 2010
Therapeutic agents useful for treating pain
PURDUE PHARMA LP31 citations93
US8946253B2Feb 3, 2015
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP23 citations92
US11236098B2Feb 1, 2022
Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
PURDUE PHARMA LP2 citations84
US9096606B2Aug 4, 2015
Quarternized buprenorphine analogs
PURDUE PHARMA LP11 citations84
US8957084B2Feb 17, 2015
7,8-cyclicmorphinan analogs
PURDUE PHARMA LP18 citations84
US8030310B2Oct 4, 2011
Therapeutic agents useful for treating pain
PURDUE PHARMA LP8 citations84
US7696207B2Apr 13, 2010
Therapeutic agents useful for treating pain
PURDUE PHARMA LP16 citations84
US7696208B2Apr 13, 2010
Therapeutic agents useful for treating pain
PURDUE PHARMA LP15 citations84
US9872856B2Jan 23, 2018
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP3 citations83
US7799786B2Sep 21, 2010
Therapeutic agents useful for treating pain
PURDUE PHARMA LP7 citations73
US10398690B2Sep 3, 2019
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP1 citations72
US9867817B2Jan 16, 2018
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP2 citations72
US9855262B2Jan 2, 2018
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP2 citations72
US9849124B2Dec 26, 2017
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP2 citations72
US9662326B2May 30, 2017
Systems for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP2 citations72
US11738023B2Aug 29, 2023
Treatment and prevention of sleep disorders
PURDUE PHARMA LP2 citations71
US10974081B2Apr 13, 2021
Treatment and prevention of sleep disorders
PURDUE PHARMA LP2 citations71
US9763955B2Sep 19, 2017
Methods and compositions for decreasing gastric emptying
PURDUE PHARMA LP3 citations69
US9931337B2Apr 3, 2018
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PURDUE PHARMA LP2 citations68
EURO CELTIQUE SA
11 patentsUS7342017B2Mar 11, 2008
1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety
EURO CELTIQUE SA19 citations93
US7262194B2Aug 28, 2007
Therapeutic agents useful for treating pain
EURO CELTIQUE SA22 citations93
US7022714B2Apr 4, 2006
Aryl substituted benzimidazoles and their use as sodium channel blockers
EURO CELTIQUE SA45 citations93
US6974818B2Dec 13, 2005
1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
EURO CELTIQUE SA39 citations93
US6825205B2Nov 30, 2004
N-substituted hydromorphones and the use thereof
EURO CELTIQUE SA25 citations93
US7279493B2Oct 9, 2007
Therapeutic agents useful for treating pain
EURO CELTIQUE SA23 citations92
US7169782B2Jan 30, 2007
Aryl substituted thiazolidinones and the use thereof
EURO CELTIQUE SA43 citations92
US7256193B2Aug 14, 2007
Therapeutic agents useful for treating pain
EURO CELTIQUE SA27 citations89
US7229993B2Jun 12, 2007
Aryl substituted pyrimidines and the use thereof
EURO CELTIQUE SA45 citations89
US7071335B2Jul 4, 2006
2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
EURO CELTIQUE SA26 citations89
US6864261B2Mar 8, 2005
Therapeutic agents useful for treating pain
EURO CELTIQUE SA18 citations82
KYLE DONALD J
9 patentsUS9221831B2Dec 29, 2015
Buprenorphine analogs
KYLE DONALD J25 citations92
US9212139B2Dec 15, 2015
Aryl substituted indoles and their use as blockers of sodium channels
KYLE DONALD J22 citations92
US9120752B2Sep 1, 2015
Pyridine compounds as sodium channel blockers
KYLE DONALD J27 citations92
US8530494B2Sep 10, 2013
Buprenophine analogs
KYLE DONALD J22 citations88
US8703962B2Apr 22, 2014
Monocyclic compounds and their use as TRPV1 ligands
KYLE DONALD J8 citations84
US8426594B2Apr 23, 2013
Benzomorphan compounds
KYLE DONALD J18 citations84
US8227467B2Jul 24, 2012
Therapeutic agents useful for treating pain
KYLE DONALD J9 citations84
US9109007B2Aug 18, 2015
MHC-I restricted epitopes containing non-natural amino acid residues
KYLE DONALD J10 citations82
US8546388B2Oct 1, 2013
Heterocyclic TRPV1 receptor ligands
KYLE DONALD J3 citations63
SCIOS NOVA INC
5 patentsUS5385889AJan 31, 1995
Bradykinin antagonist peptides
SCIOS NOVA INC22 citations90
US5541286AJul 30, 1996
Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids
SCIOS NOVA INC12 citations74
US5444048AAug 22, 1995
Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids
SCIOS NOVA INC13 citations74
US5552383ASep 3, 1996
Bradykinin antagonist pseudopeptide derivatives of aminoalkanoic acids and related olefins
SCIOS NOVA INC3 citations63
US5521158AMay 28, 1996
Pseudopeptide bradykinin receptor antagonists
SCIOS NOVA INC2 citations63
NOVA PHARM CORP
3 patentsUS5063245ANov 5, 1991
Corticotropin-releasing factor antagonism compounds
NOVA PHARM CORP131 citations94
US4761405AAug 2, 1988
Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
NOVA PHARM CORP33 citations92
US5049555ASep 17, 1991
Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
NOVA PHARM CORP18 citations69
PRODAN CAMELIA
1 patentPARK JAE HYUN
1 patentSCIOS INC
1 patentShowing the top 50 of 66 patents by PatentIndex Score.